VIDEO: Sozinibercept combination therapy in PCV results in marked visual acuity gain
Click Here to Manage Email Alerts
BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Gemmy Cheung, MD, PhD, expresses satisfaction with the effects of sozinibercept in patients with polypoidal choroidal vasculopathy, or PCV.
In a phase 2b study, sozinibercept (Opthea) administered in combination with ranibizumab showed superior outcomes compared with ranibizumab monotherapy in the overall population of patients with neovascular age-related macular degeneration.
“In particular, what is very exciting for me is that in the PCV subgroup of patients we saw a marked improvement in visual acuity gain in the combination arm compared to the monotherapy arm,” Cheung said.
Cheung said PCV is a particularly hard-to-treat group of patients with great heterogeneity, and she looks forward to seeing the results replicated in the phase 3 COAST and ShORe trials.
Collapse
Cheung G, et al. Intravitreal sozinibercept (anti-VEGF-C/D ‘trap’) combined with ranibizumab for the treatment of polypoidal choroidal vasculopathy: A predefined phase 2b subgroup analysis. Presented at: Euretina congress; Sept. 19-22, 2024; Barcelona, Spain.
Read more about
Click Here to Manage Email Alerts